Skip to content

The clinical effect of enhancing adductor co-contraction in Subacromial Pain Syndrome. A prospective single-centre randomised controlled trial

The clinical effect of enhancing adductor co-contraction in Subacromial Pain Syndrome. A prospective single-centre randomised controlled trial - CoCon trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55220
Enrollment
80
Registered
2019-12-05
Start date
2020-11-23
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronische schouderpijn chronic shoulder pain SAPS Subacromial pain syndrome

Interventions

The patients will be randomly allocated to either the control (n=40) intervention group (n=40). All patients will receive standard-care treatment (information provided by the treating physician, rel

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to participate in this study, a subject must meet all of the following criteria - Chronic shoulder pain (>3months). - Suspicion of subacromial origin of pain (e.g. combination of positive painful arc test, Hawkins-Kennedy test and empty can test). - Presence of conventional ultrasonography. - Presence of conventional radiographs.

Exclusion criteria

Exclusion criteria: - Younger than 18 years of age; - History of fracture or dislocation of the shoulder; - History of surgery around the shoulder; - Clinical and/or radiographic signs of comorbidities or alternative diagnoses of the affected shoulder (glenohumeral instability, glenohumeral/acromioclavicular osteoarthritis or arthritis, rheumatic disorder, history of trauma of the affected shoulder, capsulitis adhesiva, full thickness rotator cuff rupture, cervical radiculopathy, plexus lesions). - Tendinitis calcarea >3mm, although part of saps; requires different treatment methods. - Symptomatic cervical spine pathology; - Neoplasms; - Pregnancy; - Cognitive impairment; - Electronic implants (e.g. Implantable Cardioverter Defibrillator, pacemaker); - Insufficient Dutch language skills; - Refusing physical therapy treatment (for example, due to the absence of reimbursement); - Refusing ultrasound guided subacromial corticosteroid injection; - No informed consent.

Design outcomes

Primary

MeasureTime frame
Clinical outcomes are pain (Visual Analogue Scale), arm-shoulder function (Constant score).

Secondary

MeasureTime frame
Bio-physical-social health (RAND-36, Shoulder Rating Questionnaire) and, self-reported quality of life (Western Ontario Rotator Cuff index). Co-contraction as assessed with EMG will be expressed using the Activation Ratio ([AR]; range [-1 to1]), indicating the task-related amount of antagonist activation relative to the same muscle*s degree of agonistic activation, corresponding to 1 in case of pure agonist muscle activation and -1 in case of pure antagonistic activation. Furthermore, movement complexity and proprioception, factors that potentially associate with the clinical course of SAPS will be assessed using electromagnetic motion analysis (Flock of Birds, FoB). Lastly, we will evaluate the content of care provided and compliance of the patients by asking the patients to fill out a registration form on the frequency, duration and content of treatment.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)